검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | pembrolizumab (Keytruda, Capecitabine Tablets + Oxaliplatin, Trastuzumab + Pembrolizumab + CAPOX, Trastuzumab + Pembrolizumab + CAPOX( Capecitabine Tablets + Oxaliplatin) or FP (Fluorouracil Injection+Cisplatin)) Roche / Genentech·Patients With Unresectable Locally… ORR 80% |
|---|---|
Overview Program | Trastuzumab + Pembrolizumab + CAPOX( Capecitabine Tablets + Oxaliplatin) or FP (Fluorouracil Injection+Cisplatin) |
Overview Company | Roche / Genentech |
Overview Modality | ANTIBODY |
Overview Target | Patients With Unresectable Locally Advan |
Overview Indication | Patients With Unresectable Locally Advanced or Metastatic Untreated Gastric or Gastroesophageal Junction Adenocarcinoma |
Overview Phase | PHASE_3 |
Overview Status | RECRUITING |
Toxicology Major finding | Protective effect of N-acetylcysteine on oxaliplatin-induced neurotoxicity in patients with colorectal and gastric cancers: A randomized, double blind, placebo-controlled, clinical trial.. Neuropathy is one of the most prevalent and dose-limiting side effects of platinum chemotherapeutic agents. N-acetylcysteine is an antioxidant thiol which is able to increase whole blood concentration of glutath… |
Clinical Primary efficacy | ORR 80% |
Clinical ORR | 80.0% |
Clinical Result source | ClinicalTrials.gov NCT04430738 |
Clinical Data Tier / Score | A · 48 |
Clinical Program phase | PHASE_3 |
Clinical Clinical sync | 2026년 5월 22일 (52일 전 · 갱신 권장) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | pembrolizumab (Keytruda, Capecitabine Tablets + Oxaliplatin, Trastuzumab + Pembrolizumab + CAPOX, Trastuzumab + Pembrolizumab + CAPOX( Capecitabine Tablets + Oxaliplatin) or FP (Fluorouracil Injection+Cisplatin)) Roche / Genentech·Patients With Unresectable Locally… ORR 80% |
|---|---|
Overview Program | Trastuzumab + Pembrolizumab + CAPOX( Capecitabine Tablets + Oxaliplatin) or FP (Fluorouracil Injection+Cisplatin) |
Overview Company | Roche / Genentech |
Overview Modality | ANTIBODY |
Overview Target | Patients With Unresectable Locally Advan |
Overview Indication | Patients With Unresectable Locally Advanced or Metastatic Untreated Gastric or Gastroesophageal Junction Adenocarcinoma |
Overview Phase | PHASE_3 |
Overview Status | RECRUITING |
Toxicology Major finding | Protective effect of N-acetylcysteine on oxaliplatin-induced neurotoxicity in patients with colorectal and gastric cancers: A randomized, double blind, placebo-controlled, clinical trial.. Neuropathy is one of the most prevalent and dose-limiting side effects of platinum chemotherapeutic agents. N-acetylcysteine is an antioxidant thiol which is able to increase whole blood concentration of glutath… |
Clinical Primary efficacy | ORR 80% |
Clinical ORR | 80.0% |
Clinical Result source | ClinicalTrials.gov NCT04430738 |
Clinical Data Tier / Score | A · 48 |
Clinical Program phase | PHASE_3 |
Clinical Clinical sync | 2026년 5월 22일 (52일 전 · 갱신 권장) |
추천 비교
추천 비교